LabCorp/Myriad Genetics
This article was originally published in The Gray Sheet
Executive Summary
Myriad predictive medicine products, including the BracAnalysis test for assessing a woman's risk of developing breast or ovarian cancer, will be distributed by LabCorp's 600-rep U.S. sales force in addition to Myriad's 85-person oncology sales force, under an exclusive marketing alliance announced Dec. 4...
You may also be interested in...
Myriad Genetics DTC Ads For BRACAnalysis To Focus On Prevention Market
Myriad Genetics will concentrate direct-to-consumer advertising in Atlanta and Denver for its BRACAnalysis breast and ovarian cancer genetic predisposition testing service as the firm moves beyond physician education as a sole means of promotion
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.